0 26

Cited 0 times in

Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study

Authors
 Chung Ryul Oh  ;  Jung Yong Hong  ;  Jee Hung Kim  ;  Ji Sung Lee  ;  Hyo Song Kim  ;  Tae Won Kim  ;  Jin-Hee Ahn  ;  Jeong Eun Kim 
Citation
 TARGETED ONCOLOGY, Vol.15(4) : 485-493, 2020-06 
Journal Title
 TARGETED ONCOLOGY 
ISSN
 1776-2596 
Issue Date
2020-06
Abstract
Background: Pazopanib is the only tyrosine kinase inhibitor approved for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy, but there have been limited real-world data on pazopanib for the treatment of advanced STS. Objective: We aimed to evaluate clinical outcomes of pazopanib in patients with multiple histologic STS types in real-world settings. Patients and methods: We retrospectively analyzed clinical data of Korean patients with advanced STS treated with pazopanib between 2008 and 2019. Outcomes of interest included treatment response, survival according to histologic subtypes, and adverse events. Results: The analysis included 347 STS patients. The disease control rate for all pazopanib-treated patients was 54.8% (95% confidence interval (CI) 49.5-60.0); 54 patients (15.6%) achieved a partial response and 136 (39.2%) had stable disease. Patients with alveolar soft-part sarcoma (ASPS; 90%), solitary fibrous tumor (SFT; 88.2%), synovial sarcoma (66.7%), leiomyosarcoma (61.1%), and undifferentiated pleomorphic sarcoma (59.6%) showed higher disease control rates than those with other STS subtypes. Overall, median progression-free survival (PFS) and overall survival (OS) were 5.3 months (95% CI 4.5-6.0) and 12 months (95% CI 10-14), respectively. Noticeable survival outcomes occurred in patients with ASPS and SFT, with a median PFS of 24.5 (95% CI 2.5-30.0) and 13.0 (95% CI 3.0-21.3) months, respectively. The median OS of patients with ASPS and SFT was 48 (95% CI 17-52) and 32 (95% CI 19-66) months, respectively. Adverse drug reactions occurred in 170 patients (49.0%) but were not life-threatening. Conclusions: This real-world data analysis showed acceptable efficacy and tolerability of pazopanib in patients pretreated with cytotoxic chemotherapy for advanced STS, with favorable treatment outcomes for ASPS and SFT.
Full Text
https://link.springer.com/article/10.1007%2Fs11523-020-00731-z
DOI
10.1007/s11523-020-00731-z
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jee Hung(김지형) ORCID logo https://orcid.org/0000-0002-9044-8540
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180266
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links